Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.

@article{Trippoli1998TreatmentsFN,
  title={Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.},
  author={Sabrina Trippoli and Andrea Messori and P. Becagli and Renato Alterini and Enrico Tendi},
  journal={Oncology reports},
  year={1998},
  volume={5 6},
  pages={1475-82}
}
The main therapeutic options currently available to induce remission in newly diagnosed cases of multiple myeloma include: i) melphalan at conventional doses without concurrent administration of interferon; ii) melphalan at conventional dose combined with interferon; iii) autologous bone marrow transplantation (ABMT). We conducted an analysis of the survival data reported in five large-scale published clinical trials and we evaluated the cost-effectiveness ratio. We determined the mean lifetime… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Does Medicare have an implicit cost-effectiveness threshold?

Medical decision making : an international journal of the Society for Medical Decision Making • 2010

Understanding novel therapeutic agents for multiple myeloma.

Clinical journal of oncology nursing • 2003
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-4 of 4 references

Maintenance treatment with interferon in multiple myeloma: a survival meta-analysis

S Trippoli, P Becagli, A Messori, E. Tendi
Clinical Drug Investigation • 1997

Similar Papers

Loading similar papers…